Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Tiziana Life Sciences ( (TLSA) ) is now available.
On December 15, 2025, Tiziana Life Sciences announced that its CEO, Ivor Elrifi, purchased 163,400 shares of the company’s common stock, increasing his total holdings to 357,848 shares. This move signifies confidence in the company’s direction and its ongoing development of intranasal foralumab, a novel immunomodulation therapy. The announcement may positively impact stakeholder perception and market confidence in Tiziana’s innovative approaches to treating neurodegenerative diseases.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using transformational drug delivery technologies. The company’s lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody currently in clinical development for treating neuroinflammatory and neurodegenerative diseases. Tiziana’s innovative nasal approach aims to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods.
Average Trading Volume: 323,079
Technical Sentiment Signal: Buy
Current Market Cap: $198.4M
For a thorough assessment of TLSA stock, go to TipRanks’ Stock Analysis page.